Blood: The effect of Getuzumab ozogamicin treatment on MRD and recurrence risk in patients with NPM1 mutation AML.

Monitoring detectable residual lesions (MRDs) provides prognostic information for patients with acute myeloid leukemia (AML) with 1 mutation in nuclear phosphorus protein 1 (NPM1mut) and is a reliable tool for evaluating treatment effectiveness in clinical trials.
Schwoerer and others detected NPM1mut transcript levels through RQ-PCR and assessed the effect of NPM1mut's MRD on prognostication and the effect of Gitto monoantiza ozogamicin (GO) on NPM1 mutation levels and cumulative recurrence rates (CIR) in NPM1 mutant patients in random Phase III AMLSG 09-09 trials.
(effects of reduced levels of NPM mutation transcripts after two courses of treatment on cumulative recurrence rates) were analyzed in 3,733 bone marrow (BM) and 3,793 extrinsic blood (PB) samples from 469 patients.
after 2 cycles of treatment and at the end of treatment (EOT), NPM1mut transcription level log10 in BM and PB decreased significantly with a significant correlation between s3 and MRD transsulsion and CIR rate.
in multivarivariance analysis, mrD continued positive is a factor in poor BM and PB prognosms.
in terms of treatment effectiveness, the mid-level of transcription of NPM1-mut in GO group patients was significantly lower across all treatment cycles, resulting in a significantly higher proportion of MRD-negative patients at EOT (56% vs 41% ;P s 0.01).
with MRD-positive patients with GO treatment, the transcription level of NPM1-mut decreased significantly after two courses, and the CIR rate decreased significantly (4 years CIR 29.3% vs 45.7%, P .009).
in summary, after adding GO to intensive chemotherapy in NPM1mut AML patients, the transcription level of NPM1mut decreased significantly and the recurrence rate decreased significantly in all treatment cycles.
.